Inhibikase Therapeutics (IKT) Accounts Payables (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Accounts Payables data on file, last reported at $1.6 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $1.6 million, down 6.19% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.6 million (down 6.19% YoY), and the FY2025 annual result was $1.2 million, up 22.8% from the prior year.
• Accounts Payables rose to $1.6 million in Q1 2026 per IKT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Accounts Payables peaked at $19.0 million in Q2 2023 and troughed at $620528.0 in Q3 2025.
• A 5-year average of $2.5 million and a median of $1.2 million in 2025 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2023 and 2024: Accounts Payables soared 2111.64% in 2023, then tumbled 82.26% in 2024.
• A 5-year view of Accounts Payables shows it stood at $1.2 million in 2022, then slumped by 43.82% to $646767.0 in 2023, then surged by 45.81% to $943019.0 in 2024, then increased by 22.8% to $1.2 million in 2025, then soared by 37.07% to $1.6 million in 2026.
• Business Quant data shows IKT's Accounts Payables at $1.6 million in Q1 2026, $1.2 million in Q4 2025, and $620528.0 in Q3 2025.